Pharmacologic Effects of Disopyramide on the Pathomechanism of Obstructive Hypertrophic Cardiomyopathy
This drug decreases LVOT obstruction by mitigating the effects of energy-wasting hypercontractility in HCM by blocking the sodium channels on cardiomyocytes, leading to a decrease in sodium-calcium exchanger activity, causing a fall in intracardiomyocyte calcium levels. HCM = hypertrophic cardiomyopathy; LVOT = left ventricular outflow tract.